Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment
Previous studies have reported that the regulatory function of the different c-Jun N-terminal kinases isoforms (JNK1, JNK2, and JNK3) play an essential role in neurological disorders, such as epilepsy and metabolic-cognitive alterations. Accordingly, JNKs have emerged as suitable therapeutic strategies. In fact, it has been demonstrated that some unspecific JNK inhibitors exert antidiabetic and neuroprotective effects, albeit they usually show high toxicity or lack therapeutic value. In this sense, natural specific JNK inhibitors, such as Licochalcone A, are promising candidates. Nonetheless, research on the understanding of the role of each of the JNKs remains mandatory in order to progress on the identification of new selective JNK isoform inhibitors. In the present review, a summary on the current gathered data on the role of JNKs in pathology is presented, as well as a discussion on their potential role in pathologies like epilepsy and metabolic-cognitive injury. Moreover, data on the effects of synthetic small molecule inhibitors that modulate JNK-dependent pathways in the brain and peripheral tissues is reviewed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 21(2019), 1 vom: 30. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Busquets, Oriol [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.05.2020 Date Revised 18.05.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms21010255 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305054465 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305054465 | ||
| 003 | DE-627 | ||
| 005 | 20231225120330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms21010255 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1016.xml |
| 035 | |a (DE-627)NLM305054465 | ||
| 035 | |a (NLM)31905931 | ||
| 035 | |a (PII)E255 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Busquets, Oriol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2020 | ||
| 500 | |a Date Revised 18.05.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Previous studies have reported that the regulatory function of the different c-Jun N-terminal kinases isoforms (JNK1, JNK2, and JNK3) play an essential role in neurological disorders, such as epilepsy and metabolic-cognitive alterations. Accordingly, JNKs have emerged as suitable therapeutic strategies. In fact, it has been demonstrated that some unspecific JNK inhibitors exert antidiabetic and neuroprotective effects, albeit they usually show high toxicity or lack therapeutic value. In this sense, natural specific JNK inhibitors, such as Licochalcone A, are promising candidates. Nonetheless, research on the understanding of the role of each of the JNKs remains mandatory in order to progress on the identification of new selective JNK isoform inhibitors. In the present review, a summary on the current gathered data on the role of JNKs in pathology is presented, as well as a discussion on their potential role in pathologies like epilepsy and metabolic-cognitive injury. Moreover, data on the effects of synthetic small molecule inhibitors that modulate JNK-dependent pathways in the brain and peripheral tissues is reviewed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a JNK inhibitor | |
| 650 | 4 | |a brain | |
| 650 | 4 | |a c-Jun-N-terminal kinase | |
| 650 | 4 | |a cognitive impairment | |
| 650 | 4 | |a epilepsy | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 650 | 7 | |a Protein Isoforms |2 NLM | |
| 650 | 7 | |a JNK Mitogen-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 650 | 7 | |a Mitogen-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 700 | 1 | |a Ettcheto, Miren |e verfasserin |4 aut | |
| 700 | 1 | |a Cano, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a R Manzine, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Lopez, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Espinosa-Jiménez, Triana |e verfasserin |4 aut | |
| 700 | 1 | |a Verdaguer, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Dario Castro-Torres, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Beas-Zarate, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a X Sureda, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Olloquequi, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Auladell, Carme |e verfasserin |4 aut | |
| 700 | 1 | |a Folch, Jaume |e verfasserin |4 aut | |
| 700 | 1 | |a Camins, Antoni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 21(2019), 1 vom: 30. Dez. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2019 |g number:1 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms21010255 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2019 |e 1 |b 30 |c 12 | ||